Abstract: A method of polishing a stone surface comprises pre-treating the stone surface, applying a liquid film forming composition to the stone surface, and drying the liquid film forming composition on the stone surface. The pre-treatment includes burnishing the stone surface to form a pretreated stone surface. The liquid film forming composition includes 1 to 10 wt % polymer and 0.1 to 5 wt % wax. The polymer includes acrylate polymer and/or styrene-acrylate copolymer. The dried coating has a thickness of from 0.05 mil to 0.27 mil.

Abstract: Compound selected from those of formula (I): wherein: represents an optionally substituted 5-membered nitrogen-containing heterocycle, Ak represents an alkylene chain, X represents a single bond or phenylene, R1 and R2, which may be identical or different, each represent hydrogen or alkyl, R3 represents alkyl, nitro or cyano, Y represents NR4 or CHNO2, R4 represents hydrogen or alkyl, its tautomers when they exist, its optical isomers, and addition salts thereof with a pharmaceutically acceptable acid, with the exclusion of compounds wherein, simultaneously, represents an unsubstituted 5-membered nitrogen-containing heterocycle, Ak represents —(CH2)3—, X represents a single bond, Y represents NH and R3 represents nitro. Medicinal products containing the same which are useful as dipeptidyl peptidase IV inhibitors.

Abstract: A compound of formula (I): wherein: represents an optionally substituted saturated carbon ring having from 4 to 8 ring members, R1 and R4, which may be identical or different, each represents hydrogen or acyl, R2 and R3, which may be identical or different, each represents hydrogen or alkyl, R5 and R6, which may be identical or different, each represents hydrogen or alkyl, or R5 and R6 together, with the nitrogen atom carrying them, form an optionally substituted nitrogen-containing heterocycle, stereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful for treatment of glucose intolerance or of disorders associated with hyperglycaemia.

Abstract: Compound selected from those of formula (I): 1

Abstract: Compound of formula (I): 1

Abstract: Compounds of formula (I): ##STR1## in which: R.sub.1 and R.sub.2, which are identical or different, represent a higher alkyl or higher alkenyl radical,R.sub.3 represents a pyridyl or pyrazinyl radical,their isomers and their addition salts with a pharmaceutically acceptable acid and medicaments for the reduction of plasma lipids containing the same.

Abstract: New ethanolamine benzoate compounds which can be used as medicaments and correspond to the formula: ##STR1## wherein R is as defined in the description, in the form of racemic compounds and enantiomers. These new compounds and their physiologically tolerable salts can be used therapeutically for treatment of insulin-resistance states.

Abstract: The compounds are ethanolamine benzoate compounds useful for the treatment of syndrome X, and of hypertension in patients who are insulin resistant or have one or more metabolic anomalies.A compound disclosed is S-1-(m-trifluoromethylphenyl)-2-{.beta.-{4-[2-(N-(3,3-diphenylpropionyl)am ino)ethyl] benzoyloxy}ethylamino} propane.

Abstract: New xanthine compounds of the formula: ##STR1## in which: R.sub.1 is hydrogen or alkyl from C.sub.1 to C.sub.5 inclusive;R.sub.2 is a hydrocarbon radical up to C.sub.6 having optionally a double bond, phenyl or benzyl;R.sub.3 is hydrogen, alkyl, hydroxyalkyl or dihydroxyalkyl each from C.sub.1 to C.sub.5R.sub.4 represents: ##STR2## in which: Y is hydrogen, halogen, alkyl or alkoxy from C.sub.1 to C.sub.5 or hydroxyl;Z is methylene or a straight or branched hydrocarbon radical from C.sub.2 to C.sub.5 optionally substituted by hydroxyl; andA is an amino group of the formula: ##STR3## p being 2 or 3; ##STR4## in which q is 1 or 2, and X is a single bond, oxygen or ##STR5## in which R.sub.5 is hydrogen, alkyl or alkylene up to C.sub.5, or ##STR6## in which m is an integer from 2 to 6 and R.sub.6 is alkyl from C.sub.1 to C.sub.5.

Abstract: New sulfonylurea compounds of the formula: ##STR1## in which n is 1 or 2,R is thienyl, furyl, pyridyl or phenyl optionally mono or disubstituted,R.sub.1 and R.sub.2, the same or different, each are hydrogen, halogen, (C.sub.1 to C.sub.5)-alkyl, (C.sub.1 to C.sub.5)-alkoxy, or trifluoromethyl, or together represent --CH.sub.2 --O--CH.sub.2 --,R.sub.3 is hydrogen, or hydroxy, andR.sub.4 is (C.sub.1 to C.sub.5)-alkyl, (C.sub.3 to C.sub.8)-cycloalkyl or azacycloalkyl of the formula: ##STR2## in which p is zero or an integer from 1 to 5, or azabicycloalkyl of the formula: ##STR3## in which m is 1, 2, or 3. These new compounds and physiologically tolerable salts thereof may be used as medicines especially in the treatment of diabetes.

Abstract: Piperidylbenzimidazolinone derivatives of the formula: ##STR1## in which: R.sub.1 is lower alkyl, phenyl, halophenyl, lower alkylphenyl, lower alkoxyphenyl, methylenedioxyphenyl, ethylenedioxyphenyl, thienyl, furyl or pyridyl.R.sub.2 is R'.sub.1 COO-- or R'.sub.1 --COO--CH.sub.2 -- in which R'.sub.1 has the same meanings as R.sub.1, R.sub.1 and R'.sub.1 being the same or different, or R.sub.3 NH-- in which R.sub.3 is formyl, acetyl mesyl, carbamoyl, sulfamoyl or ethoxalyl.Z is hydrogen, lower-alkyl or lower alkenyl, andT is hydrogen, lower alkyl or lower alkoxy.These compounds and physiologically tolerable acid addition salts thereof may be used as medicines especially in the treatment of autoimmune, allergic and antiinflammatory diseases and in the treatment of dyspnea especially asthmatic and bronchial dyspnea.

Abstract: Piperidylbenzimidazolinone compounds of the formula: ##STR1## in which: R is hydrogen, hydroxy, hydroxymethyl, methoxycarbonyl, formamido, acetamido, mesylamino, oxalamino, ethoxalylamino, carbamoyl ##STR2## ureido ##STR3## or sulfamoylamino ##STR4## in which R' and R" are hydrogen or lower alkyl, T is hydrogen, halogen, lower alkyl or lower alkoxy, andZ is hydrogen, lower alkyl or lower alkenyl each in straight or branched chain.These compounds and physiologically tolerable acid addition salts thereof may be used as medicines especially in the treatment of autoimmune, allergic and inflammatory diseases and in the treatment of respiratory insufficiency of asthma.

Abstract: Pyrrolidone derivatives of the formula: ##STR1## wherein R is hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl,AndY is hydrogen, saturated or unsaturated hydrocarbon radical up to C.sub.4, hydroxyethyl, hydroxypropyl or carboxymethyl.These compounds are used as medicines especially in the treatment of lipid-metabolism disorders.

Abstract: Phenoxy compounds of the formula: ##STR1## wherein R and R', which are the same or different, are hydrogen, halogen, lower alkyl, lower alkoxy, lower alkylthio, nitro, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, lower alkoxy-carbonyl or dimethylsulfamoyl.These compounds are used as medicines especially in the treatment of glucid -- and lipid -- metabolism disorders.

Abstract: Alkanolamine derivatives and their optical isomers of the formula: ##STR1## wherein: N IS 2 OR 3, ANDR.sub.1 and R.sub.2 are lower alkyl or taken together with the nitrogen to which they are bonded, they form pyrrolidinyl, piperidino, dimethyl piperidino, morpholino, 1-thiomorpholino, azabicyclo [3, 3, 0] octyl or azabicyclo [3, 2, 2] nonyl.These compounds are used as medicines especially in the treatment of obesity, atheroma or metabolic diseases requiring weight reduction and regulation.